Physical Therapists in Haskell, NJ Accepting Medicare

10 Physical Therapists found. Showing 1 - 10

Fritzie Ann Penales-cempron, PT, DPT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 182 Carter Rd, Haskell, NJ 07420 Phone: 862-200-7120

Ruth M Broderick Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 1069 Ringwood Ave, Ste 211, Haskell, NJ 07420 Phone: 973-467-7976    Fax: 973-467-7971

Professional Orthopedic And Sports Physical Therapy Of Nj, Llc Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 1069 Ringwood Ave, Haskell, NJ 07420 Phone: 973-616-9700    Fax: 973-616-9790

Edward Evanchick, P.T. Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 25 5th Ave, Haskell, NJ 07420 Phone: 973-839-6000

Professional Occupational & Physical Therapy, Pllc Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 1069 Ringwood Ave, Haskell, NJ 07420 Phone: 973-616-9700    Fax: 973-616-9760

Melinda Donohue Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 25 5th Ave, Haskell, NJ 07420 Phone: 973-839-6000

Eon Therapy Services Llc Physical Therapist Medicare: Medicare Enrolled Practice Location: 182 Carter Rd, Haskell, NJ 07420 Phone: 973-704-4619

Brielle Runfeldt Physical Therapist Medicare: Medicare Enrolled Practice Location: 1069 Ringwood Ave, Haskell, NJ 07420 Phone: 973-616-9700    Fax: 973-616-9760

Mr. John Carl Peralta Pineda, DPT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 77 Doty Rd, Haskell, NJ 07420 Phone: 917-618-9881

Danielle Burns Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 1069 Ringwood Ave, Haskell, NJ 07420 Phone: 973-616-9700    Fax: 973-616-9760

News Archive

Roche, Bristol-Myers Squibb to evaluate YERVOY and vemurafenib treatment for metastatic melanoma

Bristol-Myers Squibb Company announced today it has entered in to a clinical collaboration agreement with Roche to evaluate the utility of Bristol-Myers Squibb's CTLA-4 inhibitor, YERVOY (ipilimumab), in combination with Roche's investigational oral BRAF inhibitor, vemurafenib, in treating patients with a specific type of metastatic melanoma.

Nasdaq issues TLC Vision a noncompliance letter regarding minimum bid price

TLC Vision Corporation (NASDAQ: TLCV) (TSX: TLC) announced today that, on September 16, 2009, it received letters from The Nasdaq Stock Market indicating that, for the last 30 consecutive business days, the Company's common stock has not maintained a minimum value of publicly held shares of $15 million as required by Marketplace Rule 5450(b)(2)(C) or 5450(b)(3)(C) (the "MVPHS Rule") and the bid price of the Company's common stock has closed below the minimum $1.00 per share requirement for continued inclusion under Marketplace Rule 5450(a)(1) (the "Minimum Bid Price Rule").

New COVID-19 test is eight times faster, can help locate asymptomatic carriers

A team of Israeli researchers is using AI to develop an algorithm-based test that can speed COVID-19 testing eightfold and help locate asymptomatic carriers, funded by a grant from the Ben-Gurion University Covid-19 Effort.

Study shows hypomethylation increases through progression of multiple myeloma

DNA methylation, a modification of DNA linked to gene regulation — is altered with increasing severity in a blood cancer called multiple myeloma, according to a study by Mayo Clinic and the Translational Genomics Research Institute (TGen).

Read more Medical News

› Verified 4 days ago